CDR-Life Announces Appointment of Swethajit Biswas, MD, as Chief Medical Officer
August 23, 2022 06:00 ET
|
CDR-Life AG
ZÜRICH, Switzerland, Aug. 23, 2022 (GLOBE NEWSWIRE) -- CDR-Life Inc., a biotechnology company pioneering a new and differentiated class of highly tumor-selective immuno-oncology therapeutics...
CDR-Life Announces $76 Million Raised in Series A Funding
April 13, 2022 06:00 ET
|
CDR-Life AG
ZÜRICH, Switzerland, April 13, 2022 (GLOBE NEWSWIRE) -- CDR-Life Inc., a biotechnology company pioneering a new and differentiated class of highly tumor-specific immuno-oncology therapeutics...
CORRECTION -- CDR-Life to Present at the American Association for Cancer Research 2022 Annual Meeting
March 22, 2022 10:56 ET
|
CDR-Life AG
ZÜRICH, Switzerland, March 22, 2022 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by CDR-Life, please note that in the second paragraph of the release, the...
CDR-Life to Present at the American Association for Cancer Research 2022 Annual Meeting
March 22, 2022 07:00 ET
|
CDR-Life AG
ZÜRICH, Switzerland, March 22, 2022 (GLOBE NEWSWIRE) -- CDR-Life Inc., a biotechnology company pioneering a new and differentiated class of highly tumor-specific immuno-oncology therapeutics...
CDR-Life Announces Positive Preclinical Data on CDR101 Program Presented at the American Society of Hematology’s 2021 Annual Meeting
December 13, 2021 06:00 ET
|
CDR-Life AG
ZÜRICH, Switzerland, Dec. 13, 2021 (GLOBE NEWSWIRE) -- CDR-Life Inc., a biotechnology company pioneering a new and differentiated class of highly tumor-specific immuno-oncology therapeutics...
CDR-Life to Present at the American Society of Hematology’s 2021 Annual Meeting
November 08, 2021 09:00 ET
|
CDR-Life AG
ZÜRICH, Switzerland, Nov. 08, 2021 (GLOBE NEWSWIRE) -- CDR-Life Inc., a biotechnology company pioneering a new and differentiated class of highly tumor-specific immuno-oncology therapeutics...
CDR-Life Announces Expansion of Scientific Advisory Board
October 26, 2021 03:00 ET
|
CDR-Life AG
ZÜRICH, Switzerland, Oct. 26, 2021 (GLOBE NEWSWIRE) -- CDR-Life Inc., a biotechnology company pioneering a new and differentiated class of highly tumor-specific immuno-oncology therapeutics...
CDR-Life Announces the Advancement of Antibody Treatment for Patients with Geographic Atrophy with Development Partner Boehringer Ingelheim
September 08, 2021 03:00 ET
|
CDR-Life AG
ZÜRICH, Switzerland, Sept. 08, 2021 (GLOBE NEWSWIRE) -- CDR-Life Inc., today announced that Boehringer Ingelheim has selected an antibody fragment-based therapeutic candidate for advancement to...